Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.

Fluoroquinolones are widely used for the treatment of bacterial infections and are also second-line therapy for tuberculosis. However, fluoroquinolone resistance in patients with newly diagnosed cases of tuberculosis is not routinely assessed. We performed in vitro susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones for all culture-confirmed tuberculosis cases in adults that were diagnosed at Johns Hopkins Hospital (Baltimore) between January 1998 and March 2002. Fifty-five patients were included in the study; 19 received fluoroquinolone monotherapy before the initiation of antituberculosis therapy. Two of 55 M. tuberculosis isolates (4%; 95% CI, 1%-13%) had decreased susceptibility to fluoroquinolones, including 2 of 19 of those from patients who had received fluoroquinolones (11%; 95% CI, 1%-33%) and 0 of 36 isolates from those who had not (95% CI, 0%-10%). The 2 fluoroquinolone-resistant M. tuberculosis strains were both from patients with acquired immunodeficiency syndrome and a CD4+ lymphocyte count of <50 cells/mm3. The incidence of M. tuberculosis fluoroquinolone resistance in this small sample of patients with newly diagnosed tuberculosis was high, particularly among patients with prior fluoroquinolone exposure.

[1]  M. Tsukamura,et al.  Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[2]  S. Dorman,et al.  The rapid development of fluoroquinolone resistance in M. tuberculosis. , 2003, The New England journal of medicine.

[3]  K. Dooley,et al.  Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Karasulu,et al.  The treatment of multidrug-resistant tuberculosis in Turkey. , 2001, The New England journal of medicine.

[5]  M. Ruiz,et al.  In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. , 2001, International journal of antimicrobial agents.

[6]  E. Bouza,et al.  In Vitro Activities of Six Fluoroquinolones against 250 Clinical Isolates of Mycobacterium tuberculosisSusceptible or Resistant to First-Line Antituberculosis Drugs , 2000, Antimicrobial Agents and Chemotherapy.

[7]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Leung,et al.  Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. , 2000, Chest.

[9]  A. Vernon,et al.  Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid , 1999, The Lancet.

[10]  N. Lounis,et al.  In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.

[11]  C. Whitney,et al.  Risk factors for rifampin mono-resistant tuberculosis. , 1998, American journal of respiratory and critical care medicine.

[12]  S. Gillespie,et al.  Fluoroquinolones: a new treatment for tuberculosis? , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  T. Frieden,et al.  Rifampin-monoresistant tuberculosis in New York City, 1993-1994. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  John P. Matts,et al.  Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV‐related tuberculosis and characterization of a strain with levofloxacin monoresistance , 1997 .

[15]  R. Owens,et al.  Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS , 1997, Antimicrobial agents and chemotherapy.

[16]  W. Rom,et al.  Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. , 1996, American journal of respiratory and critical care medicine.

[17]  N. Lounis,et al.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis , 1995, Antimicrobial agents and chemotherapy.

[18]  J. Bartlett,et al.  Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection , 1994, Antimicrobial Agents and Chemotherapy.

[19]  P. Barnes,et al.  Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. , 1993, The American review of respiratory disease.

[20]  G. Schoolnik,et al.  An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. , 1992, The New England journal of medicine.

[21]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[22]  J. Enders.  Infectious Diseases Society of America , 1969 .

[23]  I. Krasnow,et al.  Preparation of tuberculosis susceptibility testing mediums by means of impregnated disks. , 1966, American journal of clinical pathology.

[24]  Henry D. Isenberg,et al.  Clinical Microbiology Procedures Handbook , 2004 .

[25]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.